ETX Stock Overview
Engages in drug discovery research activities in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
e-therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.09 |
| 52 Week High | UK£0.24 |
| 52 Week Low | UK£0.08 |
| Beta | 0.43 |
| 1 Month Change | -28.00% |
| 3 Month Change | -41.18% |
| 1 Year Change | -29.27% |
| 3 Year Change | -65.78% |
| 5 Year Change | 332.69% |
| Change since IPO | -86.67% |
Recent News & Updates
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06Shareholder Returns
| ETX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.3% | -1.0% | -0.6% |
| 1Y | -29.3% | -24.1% | 3.1% |
Return vs Industry: ETX underperformed the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: ETX underperformed the UK Market which returned 5.2% over the past year.
Price Volatility
| ETX volatility | |
|---|---|
| ETX Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ETX's share price has been volatile over the past 3 months.
Volatility Over Time: ETX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 34 | Ahmad Mortazavi | www.etherapeutics.co.uk |
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. It offers HepNet, a proprietary, hepatocyte-specific, and computational biology platform that addresses key limitations of the biopharmaceutical industry, including extracting value from big data, addressing complex diseases, and improving translatability in research and development; and GalOmic, a RNA interference (RNAi) chemistry platform, which enables the generation of GalNAc-conjugated short interfering RNA drug candidates for hepatocyte-specific gene silencing through RNAi of any target gene identified by HepNet. The company was incorporated in 2001 and is based in London, the United Kingdom.
e-therapeutics plc Fundamentals Summary
| ETX fundamental statistics | |
|---|---|
| Market cap | UK£52.59m |
| Earnings (TTM) | -UK£10.06m |
| Revenue (TTM) | UK£340.00k |
154.7x
P/S Ratio-5.2x
P/E RatioIs ETX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ETX income statement (TTM) | |
|---|---|
| Revenue | UK£340.00k |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£340.00k |
| Other Expenses | UK£10.40m |
| Earnings | -UK£10.06m |
Last Reported Earnings
Jul 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,957.65% |
| Debt/Equity Ratio | 0% |
How did ETX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/10 13:20 |
| End of Day Share Price | 2024/05/08 00:00 |
| Earnings | 2023/07/31 |
| Annual Earnings | 2023/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
e-therapeutics plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philip Morrish | Growth Equities & Company Research |
| Paul Cuddon | Numis Securities Ltd. |
| Savvas Neophitou | Panmure Liberum Historic (Panmure Gordon) |